The Value of Placental Vascularization and Placental Volume in Pregnancy in APLS

Last updated: January 24, 2020
Sponsor: Aljazeera Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Antiphospholipid Syndrome

Thrombosis

Platelet Disorders

Treatment

N/A

Clinical Study ID

NCT03505840
vocal in placenta
  • Ages 18-40
  • Female
  • Accepts Healthy Volunteers

Study Summary

Antiphospholipid antibodies are autoantibodies directed against phospholipid‐binding proteins. Among these groups of antibodies, lupus anticoagulant (LA) and anticardiolipin antibodies (aCL)

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Singleton pregnancy.

  • Gestational age of 34‐37 weeks.

  • Pregnant women with antiphospholipid syndrome

Exclusion

Exclusion Criteria:

  • Twin or multiple pregnancies.

  • Congenital fetal anomalies.

  • Gestational age of less than 34.

  • Gestational age of more than 37.

  • Women with placental or umbilical artery anomalies.

  • Antepartum hemorrhage (placental abruption, placenta previa and vasa previa).

  • Posterior placenta.

  • History of rupture of membrane.

  • Patient refusal or fall outs.

Study Design

Total Participants: 100
Study Start date:
April 24, 2018
Estimated Completion Date:
October 10, 2020

Study Description

APLS can be primary when no evidence of autoimmune disease is found, or secondary to autoimmune processes like systemic lupus erythematous (SLE) in a 40% of the cases.

Connect with a study center

  • Algazeerah

    Giza,
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.